Theragen Etex Co (XKRX:066700) Total Current Assets : ₩150,714 Mil (As of Dec. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Theragen Etex Co Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Theragen Etex Co's total current assets for the quarter that ended in Dec. 2024 was ₩150,714 Mil.

Theragen Etex Co Total Current Assets Historical Data

The historical data trend for Theragen Etex Co's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theragen Etex Co Total Current Assets Chart

Theragen Etex Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Current Assets

Get a 7-Day Free Trial

96,337.07

96,954.24

106,961.89

115,389.91

150,714.08

Theragen Etex Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Current Assets	Get a 7-Day Free Trial															115,389.91	119,347.25	126,605.76	127,395.98	150,714.08

Theragen Etex Co Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Theragen Etex Co's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	24183.019	+	67648.142	+	35831.089	+	23051.833
	=	150,714

Theragen Etex Co's Total Current Assets for the quarter that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	24183.019	+	67648.142	+	35831.089	+	23051.833
	=	150,714

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Theragen Etex Co (XKRX:066700) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Theragen Etex Co's Liquidation Value for the quarter that ended in Dec. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	24183.019	-	106458.788	+	0.75 * 63720.097	+	0.5 * 35831.089
=	-16,570

Theragen Etex Co Total Current Assets Related Terms

Thank you for viewing the detailed overview of Theragen Etex Co's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Theragen Etex Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Theragen Etex Co Ltd (XKRX:066700) » Definitions » Total Current Assets

Traded in Other Exchanges

N/A

Address

58, Sandan-ro 68-gil, Danwon-gu, Gyeonggi-do, Ansan-si, KOR

Website

http://www.theragenetex.com

Theragen Etex Co Ltd is a Korea-based company mainly engaged in the manufacturing and selling of finished pharmaceutical products and providing genome sequencing services. It also provides healthcare services. The company's operating segments include its Pharmaceutical business and the Healthcare and Genome Analysis Business. A majority of its revenue is generated from the Pharmaceutical Business which involves the manufacturing and sales of specialized and general medicine along with new drug research and development. The Healthcare and Genome Analysis Business involves DNA sequence analysis, RNA mutation genome analysis and decoding, and the distribution of non-prescription drugs for healthcare purposes. Geographically, the company derives its key revenue from the domestic market.

Theragen Etex Co Headlines

No Headlines